The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 30, 2025
Filed:
Sep. 01, 2023
Applicant:
Arvinas Operations, Inc., New Haven, CT (US);
Inventors:
Lawrence B. Snyder, Killingworth, CT (US);
Andrew P. Crew, Chester, CT (US);
Jing Wang, Milford, CT (US);
Hanqing Dong, Madison, CT (US);
Assignee:
Arvinas Operations, Inc., New Haven, CT (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/167 (2006.01); A61K 31/277 (2006.01); A61K 31/337 (2006.01); A61K 31/417 (2006.01); A61K 31/4523 (2006.01); A61K 31/4545 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61K 31/57 (2006.01); A61K 31/661 (2006.01); A61K 31/663 (2006.01); A61K 31/675 (2006.01); A61K 38/09 (2006.01); A61K 47/54 (2017.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 498/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/167 (2013.01); A61K 31/277 (2013.01); A61K 31/337 (2013.01); A61K 31/417 (2013.01); A61K 31/4523 (2013.01); A61K 31/4545 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 31/57 (2013.01); A61K 31/661 (2013.01); A61K 31/663 (2013.01); A61K 31/675 (2013.01); A61K 38/09 (2013.01); A61K 47/545 (2017.08); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 498/10 (2013.01);
Abstract
This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.